Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
IRCCS Humanitas Research Hospital, Rozzano, Italy.
Mod Rheumatol Case Rep. 2023 Jun 19;7(2):440-443. doi: 10.1093/mrcr/rxad005.
We here report the first case of anti-proteinase 3-positive anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis following the severe acute respiratory syndrome coronavirus 2 Pfizer-BioNTech vaccine presenting with prominent liver involvement and alveolar haemorrhage. Two weeks after vaccination, a 49-year-old man developed inflammatory arthralgias and hypertransaminasaemia. Two months later, fever and haemoptysis appeared; the patient tested positive for anti-proteinase 3 autoantibodies. High-dose steroids and rituximab were started, and complete remission was achieved. Systemic autoimmune diseases, including ANCA-associated vasculitis, should always be considered in the differential diagnosis of hypertransaminasaemia, especially when the clinical context is suspicious.
我们在此报告首例严重急性呼吸综合征冠状病毒 2 型辉瑞-生物技术疫苗接种后抗蛋白酶 3 阳性抗中性粒细胞胞质抗体(ANCA)相关性血管炎病例,其表现为明显的肝受累和肺泡出血。接种疫苗后 2 周,一名 49 岁男子出现炎症性关节痛和高氨基转移酶血症。2 个月后,出现发热和咯血;患者抗蛋白酶 3 自身抗体检测呈阳性。开始使用大剂量类固醇和利妥昔单抗治疗,患者达到完全缓解。在鉴别诊断高氨基转移酶血症时,应始终考虑包括 ANCA 相关性血管炎在内的系统性自身免疫性疾病,尤其是在临床情况可疑时。